Skip to main content
GenFleet Therapeutics (Shanghai) Inc. logo

GenFleet Therapeutics (Shanghai) Inc. — Investor Relations & Filings

Ticker · 2595 HKEX Manufacturing
Open in API
Filings indexed 667 across all filing types
Latest filing 2026-03-02 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2595

About GenFleet Therapeutics (Shanghai) Inc.

http://www.genfleet.com

GenFleet Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies in oncology and immunology. Established in 2017, the company employs a "Global New" strategy centered on source innovation, targeting novel biological pathways and indications that have not yet achieved clinical validation to build a differentiated, high-value pipeline. GenFleet has demonstrated particular expertise in developing RAS-pathway targeted therapies. The company integrates international clinical and commercial development routes, utilizing global strategic cooperation to facilitate the future entry of its products into worldwide markets.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT GFH375 Granted with First Breakthrough Therapy Designation in China for a KRAS G12D Inhibitor Treating Non-small Cell Lung Cancer
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by GenFleet Therapeutics regarding a business update (Breakthrough Therapy Designation for a drug candidate). It follows the standard format of a Hong Kong Stock Exchange regulatory announcement, including a disclaimer, company details, and a 'By order of the Board' signature. Since it does not fit into specific categories like financial reports, dividends, or director dealings, it falls under the general regulatory filing category.
2026-03-02 English
VOLUNTARY ANNOUNCEMENT INCLUSION AS A CONSTITUENT OF HANG SENG INDEX SERIES AND MSCI INDEX
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by GenFleet Therapeutics regarding its inclusion in the Hang Seng Index Series and MSCI Index. It does not fit into specific categories like financial reports, dividend notices, or director dealings. As it is a general regulatory announcement regarding company status and market index inclusion, it falls under the 'Regulatory Filings' (RNS) category.
2026-02-13 English
ARTICLES OF ASSOCIATION
Share Issue/Capital Change Classification · 1% confidence The document is the 'Articles of Association' of GenFleet Therapeutics (Shanghai) Inc. This document outlines the company's internal governance, share structure, board responsibilities, and operational rules. In the context of corporate filings, the Articles of Association are a fundamental governance document that defines the company's legal framework and is typically categorized under Governance Information (CGR).
2026-02-09 English
(1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 9, 2026; AND (2) ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement detailing the poll results of an Extraordinary General Meeting (EGM) held on February 9, 2026. It explicitly lists the voting outcomes for various resolutions, including special resolutions regarding share incentive schemes and amendments to the Articles of Association. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2026-02-09 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2026
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Exchanges and Clearing Limited. This is a standard regulatory filing required by the HKEX for listed companies to report movements in securities, share capital, and public float sufficiency. It does not fit into specific categories like 'Share Issue' (which is for specific events) or 'Transaction in Own Shares' (which is for buybacks), but rather serves as a periodic regulatory disclosure of capital structure. Therefore, it is best classified as a Regulatory Filing (RNS).
2026-02-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Stock Exchange (HKEX). This is a standard regulatory filing required by the Exchange Listing Rules to report movements in securities, share capital, and public float sufficiency on a monthly basis. It does not fit into specific categories like '10-K' (annual report), 'ER' (earnings release), or 'SHA' (specific share issue announcement), as it is a recurring regulatory compliance disclosure. Therefore, it is classified under the fallback category for regulatory filings.
2026-02-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.